First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease

Introduction: The effect of local ablative therapy (LAT) for oligoprogressive epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) remains undetermined. This study aimed to investigate the survival benefit of addition of LAT to EGFR-TKIs in EGFR-mutant NSCLC patients w...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Cancer
Main Authors: Xu, Qinghua, Liu, Hui, Meng, Shuyan, Jiang, Tao, Li, Xuefei, Liang, Shixiong, Ren, Shengxiang, Zhou, Caicun
Formato: Artigo
Idioma:Inglês
Publicado: Ivyspring International Publisher 2019
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6360299/
https://ncbi.nlm.nih.gov/pubmed/30719148
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.26494
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares